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Abstract
A great majority of genetic markers discovered in recent genome-wide association studies have small effect sizes, and they
explain only a small fraction of the genetic contribution to the diseases. How many more variants can we expect to
discover and what study sizes are needed? We derive the connection between the cumulative risk of the SNP variants to
the latent genetic risk model and heritability of the disease. We determine the sample size required for case-control studies
in order to achieve a certain expected number of discoveries in a collection of most significant SNPs. Assuming similar
allele frequencies and effect sizes of the currently validated SNPs, complex phenotypes such as type-2 diabetes would
need approximately 800 variants to explain its 40% heritability. Much smaller numbers of variants are needed if we assume
rare-variants but higher penetrance models. We estimate that up to 50,000 cases and an equal number of controls are
needed to discover 800 common low-penetrant variants among the top 5000 SNPs. Under common and rare low-
penetrance models, the very large studies required to discover the numerous variants are probably at the limit of practical
feasibility. Under rare-variant with medium- to high-penetrance models (odds-ratios between 1.6 and 4.0), studies
comparable in size to many existing studies are adequate provided the genotyping technology can interrogate more and
rarer variants.
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Introduction
The advent of affordable high-throughput genotyping technol-
ogy has led to numerous large-scale genome-wide association
studies. A striking and disappointing feature of the discoveries
made is the mostly small effect sizes. The first major results in type-
2 diabetes [1] reported 9 validated SNPs, one on the TCF7L2
gene having odds ratio (OR) 1.37, while the others had ORs
between 1.12 and 1.20. A co-dominant model is commonly
assumed, and the stated OR is per risk allele; we adopt the same
model throughout. A more recent meta-analysis aiming at
expanding the number of associated SNPs for type-2 diabetes
[2] combined data from 3 major studies, involving 4,549 cases and
5,579 controls, using genome-wide scans of 2.2 million typed and
imputed SNPs. The study identified 11 SNPs that were validated
in stage 2 (21,461 subjects) and stage 3 (32,514 subjects). The ORs
of these SNPs based on the combined data range from 1.05 to
1.15.
Similar results have been reported in other complex diseases: for
example, in breast cancer [3] the top 11 SNPs at final validation
stage (involving 21,860 cases and 22,578 controls) have ORs
ranging from 1.04 to 1.26. To get an overview, we downloaded the
compilation of all GWAS results from http://www.genome.gov/
26525384. As of 3 March 2009 the website includes 273
publications and 1213 SNPs. We removed studies (i) of non-
disease traits; (ii) that did not have replications; (iii) that did not
report risk allele frequencies or p-values or ORs. ORs were
computed from the largest available data, i.e. including data from
the replication studies. Following (iii), quantitative traits were
excluded because they did not report ORs. Using these criterion
we ended up with 383 SNPs from 101 studies; the list is given in
the Supplementary Material (Table S1).
The histogram in Figure 1 confirms that the great majority of
discovered SNPs have small ORs. The median OR is 1.25. Forty
percent (153/383) of the ORs are ƒ1:2; 60% (230/383) are ƒ1:3
and 80% (306/383) are ƒ1:5. Only three percent of the ORs (10/
383) are w3. The small frequency of ORs between 1 and 1.1
suggests that many existing studies are not large enough to
discover ORs in that range, and there are likely many more SNPs
with ORs in that range that remain to be discovered.
As has been commented by many authors [4,5,6], these small
effects mean that the current discoveries explain only a small
fraction of the genetic contribution to the disease. In this paper we
will address two questions: how many more disease-associated
SNPs remain to be discovered? What sample sizes are required to
discover them? The first question depends on the genetic
architecture (e.g., the allele frequencies and penetrance of the
remaining variants) that underlies the heritability of the disease.
Intuitively, given the weak effects we observe currently, a large
number of variants is required to explain a heritability of
approximately 40% for type-2 diabetes [7] or 30% for breast
cancer [8]. An alternative suggestion is that rare variants with
higher penetrance, missed by the present genotyping, explain most
of the heritability. We investigate the second question by
estimating the sample size required for a case control study
conducted to discover the multiple variants. It is not obvious to
know, for example, what is required to discover 500 common low-
penetrant variants or some other number of rare variants.
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As an illustrative case study, we consider results from type-2
diabetes, where we have 9 SNPs from [1] and 11 SNPs from [2].
OR estimates are taken from the largest available combined
sample. The specific SNP information is given in Table 1.
The distribution of the risk for type-2 diabetes attributable to
the SNPs in Table 1 is given in Figure 2. The sum of the
proportions is 100%. The dotted curve is the normal approxima-
tion. The graph shows the population heterogeneity in suscepti-
bility to diabetes, as assumed in quantitative genetic analysis (see
Materials and Methods). Assuming 10% overall prevalence of
type-2 diabetes in the population, the 5% of the population at
highest risk have 16% chance of being affected. This same group
has an OR of 2.1 relative to the average risk group, and an OR of
4.2 relative to the 5% at lowest risk. The great promise of genomic
medicine is individualized prognosis; to achieve 90% sensitivity
and 90% specificity for such a prognosis, we would need an OR of
(0.9/0.1)/(0.1/0.9)=81. This means that the current result is still
very far from the goal of individualized prognosis.
The variance of the distribution in Figure 2, reflecting the
contribution of the 20 SNPs, is 0.13. Using formula (4), the
contribution of the 20 SNPs to the liability variance is 3.8%
~0:13
 
0:13zp2 
3
     
. Compared to the known heritability of
type-2 diabetes, which is around 40% [7], this means we have
discovered only a small fraction of the potential genetic
contribution to the disease. (Poulsen et al. [7] actually reported a
wide range of heritability estimates (26% to 61%) depending how
type-2 diabetes is defined; we take 40% as an intermediate value.)
From (4), to achieve a heritability of 40%, we need var g ðÞ ~2:19,
which can be achieved by discovering more variants.
How Can We Improve the Current Results?
Discoveries of More Variants by Performing Larger and
Larger Studies. Suppose we double the number of type-2
diabetes SNPs from 20 to 40, all assumed to be independent and of
similar effect sizes to the current SNPs. Then the 5% of individuals
with the highest risk have an OR of 2.7 relative to the average risk
group, and an OR of 7.2 relative to the 5% at lowest risk. With
100 independent SNPs, these ORs increase to 4.5 and 20.5.
However, larger studies tend to discover smaller effect sizes; beside
the direct impact of increased power to detect weaker effect sizes,
larger studies also increase disease heterogeneity. Distinct disease
subtypes might be due to different risk alleles, so mixing all
different subtypes in a large study will tend to dilute the effect sizes.
Discoveries of Variants with Larger Effect Sizes
If we find 20 SNPs with twice the observed effect sizes in the
diabetes study, the odds-ratio of the 5% at the highest risk relative
to the average risk group is 4.1, and relative to the 5% at the
lowest risk is 17.0. We can search for larger effect sizes by studying
more homogeneous sub-populations, for example, those defined
by (i) more specific phenotypes (e.g. early onset cases), or (ii)
familial cases of the disease. We might also search for larger effects
among gene-gene or gene-environmental interactions, where by
‘interaction’ we mean the deviation from the log-additive model.
However, studying a more homogenous sub-population will
require (i) even larger overall sample sizes to overcome increased
multiplicity and stratification, and (ii) more detailed data on
phenotype, lifestyle and environmental factors. To illustrate the
problem in the analyses of interactions, if we start with 106
Figure 1. Distribution of 383 ORs from 101 GWA studies listed
in the Supplementary table (Table S1).
doi:10.1371/journal.pone.0007969.g001
Table 1. The top 9 SNPs from [1] (the first 9 on the first
column) and 11 SNPs from [1].
SNP Freq. OR SNP Freq. OR
Rs10811661 0.83 1.20 rs12779790 0.183 1.11
Rs4402960 0.29 1.14 rs7961581 0.269 1.09
Rs1470579 0.30 1.17 rs7578597 0.902 1.15
Rs7754840 0.31 1.12 rs4607103 0.761 1.09
Rs1111875 0.53 1.13 rs10923931 0.106 1.13
rs13266634 0.65 1.12 rs1153188 0.733 1.08
Rs7903146 0.26 1.37 rs17036101 0.927 1.15
rs5219 0.47 1.14 rs2641348 0.107 1.10
Rs1801282 0.86 1.14 rs9472138 0.282 1.06
rs864745 0.501 1.10 rs10490072 0.724 1.05
‘Freq.’ refers to the frequency and ‘OR’ the odds-ratio of the risk allele.
doi:10.1371/journal.pone.0007969.t001
Figure 2. Distribution of latent genetic risk derived for the
type-2 diabetes example, computed using (1) and (2).
doi:10.1371/journal.pone.0007969.g002
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to search among 1012 hypotheses, so severe constraints are needed
to make the search practically feasible and statistically meaningful.
It is worth noting that gene-gene interactions, which are clearly
plausible, also tend to generate rare composite-genotypes. Two
relatively common SNPs, each with a MAF of 0.3, can for example
produce an interacting genotype with a MAF of 0:34 ~0:0081 ðÞ ,
assuming independence and interaction among the minor
homozygous alleles only. The problem is worse if several SNPs
are interacting. So the detection of gene-gene interactions will be
at least as hard as detection of rare variants.
Different types of variants, for example copy-number variants,
insertion/deletionorepigeneticchangesasmeasured bymethylation
status, have the potential for enlarging the search space for disease-
causing variants. To contribute beyond what is already captured by
the SNP array platforms, these variants have to be independent
(not in linkage disequilibrium) with the existing SNP markers.
How Many More Disease Variants Can We Discover?
The number of variants to be discovered is determined by (i) the
total genetic contribution to the disease, and (ii) the genetic
‘architecture’ of the disease. This architecture is a function of the
allele frequencies and effect sizes; for example, we might have com-
mon low-penetrant variants or rare high-penetrant variants. Given
the current bias in genotyping common SNPs, it seems unlikely that
we have missed many common-variants with medium or high effect-
sizes, as they would have been discovered in the large-sample studies.
What is more likely to remain are the common variants of
loweffect-sizes,orrarevariants with low,mediumor high effect-sizes.
Let us first assume that the causal variants to be discovered are
similar in ORs and allele frequencies to the SNPs found in [2]. Note
that the OR range (1.05 to 1.15) in [2] is already lower than the range
from an earlier study (1.12 to 1.20, excluding the TCF7L2, from [1]).
To explain the 40% heritability of type-2 diabetes we need 812 variants
(including the 20 variants already discovered). Figure 3 (solid curve)
shows the number of causal variants as a function of the heritability for
the common-variant model with low effect-sizes.
To get a better understanding we compare several genetic
models with various distributions of MAFs and effect sizes as
follows, with details given in Table 2:
A. Common-low: this is as described above paragraph.
B. Modest-low: the MAFs are half of the MAFs in A, but with
the same effect sizes.
C. Rare-low: the MAFs are one-fifth of the MAFs in A, but with
the same effect sizes.
D. Rare-medium: the MAFs are one-fifth of the MAFs in A, but
the log-ORs are 5-times larger.
E. Rare-high: the MAFs are one-tenth of the MAFs in A, but the
log-ORs are 10-times larger.
F. Very-rare-high: the MAFs are one-hundredth of the MAFs in
A, but the log-ORs are 10-times larger.
Figure 3 also shows the number of causal variants as a function
of the heritability for the different genetic architectures. As
expected, the worst in terms of potential discoveries is rare-variant
low-penetrant model (C), which requires 3114 variants to explain a
heritability of 0.4. In contrast, for model E, where we set the allele
frequencies to be 10-times smaller (MAF range 0.0073 to 0.05) and
log ORs 10-times larger (OR range 1.63 to 4.05), we only need 80
rare variants. Very-rare variants (model F, with MAF range
0.00073 to 0.005) are challenging enough just to observe them in a
study, and we need approximately 600 of them even with relatively
high effect-sizes. These extreme models pose other statistical
difficulties, which we discuss in the next section.
Sample Size Issues
How large should our study be to capture multiple causal variants?
Most sample size computations for association studies are based on
the power to detect a single variant, allowing for the standard
significance level. Such an approach is not applicable to deal with the
discovery of multiple causal variants, since we then have to consider
the impact of multiple testing problem. We thus adapt a method from
microarray gene-expression studies [9], where we consider the
expectednumberoftruepositivesin alistoftopSNPs.Because ofLD
and multiple SNP markers within a haplotype block, a single causal
variant may be tagged by multiple significant markers. To be
concrete, assume that an average of 3 markers will be significant for
each causal variant; this does not affect our conclusions. For the null
SNPs, we assume that the MAFs vary according to this distribution:
MAF 0.05 0.1 0.2 0.3 0.4
proportion 0.35 0.25 0.15 0.13 0.12
This roughly follows the MAF distribution of the SNPs in
chromosome 22 of the control group in the Wellcome-Trust case-
control consortium data [10]. The exact shape is not crucial for
our computations.
For the causal variants, under each model, the MAFs and ORs
follow the distributions in Table 2. For each model, the MAFs are
discretized into 5 equally-spaced values within the assumed range,
and each MAF has equal proportion. The OR range is similarly
split. For example, for model A, the MAFs are distributed with
equal proportion at (0.073, 0.180, 0.286, 0.393, 0.500), the ORs
are (1.15, 1.125, 1.100, 1.075, 1.05).
We assume that we use arrays with 1 M markers for models A
and B. To be able to capture rare variants, we assume 10 M-
marker arrays for model D, and 100M-marker arrays for model E.
Figure 4 shows the expected number of causal variants that will be
discovered as a function of the number of cases in a case-control
Figure 3. The number of variants required to explain the
corresponding heritability. The labels A–F refer to the genetic
models given in Table 2.
doi:10.1371/journal.pone.0007969.g003
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capture about 330 of the 812 causal variants in the top 1000 SNPs,
we need a study with at least 25,000 cases and 25,000 controls. (Since
we assume 3 significant markers per causal variant, when all the
causal variants are discovered with large enough sample size, the top
1000 SNPs will in the average contain the top 333 causal SNPs.) In
sucha study, we expect about 600ofthe 812 causalvariantsin the top
5000 SNPs. The large number of null SNPs in this list of top 5000
SNPs means that further validation studies are required to identify the
causal variants. Approximately 50,000 cases and 50,000 controls are
needed to capture the 812 causal variants among the top 5000 SNPs.
The worse scenario regarding sample size is model B, the model
of rare variants with low effect-sizes, where at least 125,000 cases
and 125,000 controls are needed to discover approximately 1400
variants among the top 5000 SNPs. However, the detection of rare
variants in models D and E is surprisingly within reach with the
kind of sample sizes achieved by consortium studies performed
today. This is of course a function of the assumed MAFs and ORs;
Table 2. Various models of genetic architecture and the number of variants needed to explain a heritability of 0.4.
Scenario by Freq- Effect-sizes Range of MAFs Range of ORs Number of variants for h2~0:4
A. Common-low 0.073–0.499 1.05–1.15 812
B. Modest-low 0.0365–0.2495 1.05–1.15 1368
C. Rare-low 0.0146–0.0998 1.05–1.15 3114
D. Rare-medium 0.0146–0.0998 1.28–2.01 144
E. Rare-high 0.0073–0.0499 1.63–4.05 80
F. Very-rare-high 0.00073–0.00499 1.63–4.05 608
doi:10.1371/journal.pone.0007969.t002
Figure 4. The expected number of discoveries of causal variants as a function of the number of cases in a case-control study, with
equal number of controls. The models refer to those in Table 2 in terms of the range of MAFs and ORs of the risk alleles of non-null variants. For
models A and B, we plot the expected number of discoveries among the top 1000 (solid), 2000 (dashed) and 5000 SNPs (dotted); for models D and E,
they among the top 100 (solid), 200 (dashed) and 500 SNPs (dotted).
doi:10.1371/journal.pone.0007969.g004
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requirement will increase.
Discussion
Our current search in genome-wide association studies (GWAS)
is based on the common-disease common-variant model. It might
be argued that the distribution of validated SNPs supports this
model [5]; for example, 18 of the 20 validated SNPs for type-2
diabetes in Table 1 have MAFs w10%. Of the 383 SNPs from the
recent GWAS (see Introduction), 87% (335/383) have MAFs
w0:1. This observation is of course biased since statistical power is
higher for larger MAFs and the current genotyping technology
prioritizes SNPs with larger MAFs. The current array technology
from Affymetrix and Illumina, directly and indirectly via LD, has a
good coverage of the HapMap 4 M SNPs. However, an
assessment in a resequenced region of 76 genes [11] shows that
the current products, including Affymetrix 6.0 and Illumina 1 M,
have substantially low coverage of the complete common variation
with MAFs §0:05. So there could still be other common causal
variants that are not yet covered by existing arrays.
We have used heritability as the basis to estimate the number of
remaining variants, where heritability is defined as the genetic
contribution to the variance of the liability of the disease. In
comparison, Yang et al. [12] used the population attribution
fraction (PAF), roughly the genetic contribution to the proportion
of the disease in the population. While it is straightforward to
compute the PAF from a set of known SNPs, it is not obvious how
to get the total PAF from all the (known and unknown) causal
variants. This is a disadvantage compared to our approach, since
heritability is commonly reported for most diseases.
Our computation shows that a large number of low-penetrant
variants are needed to account for a heritability of 30–40%. This
poses a major challenge, requiring enormous sample sizes (e.g.
model B in Figure 4 to discover these variants. While such large
samples are feasible in some existing consortia, a complicating
factor that comes with larger and larger studies is the potential
dilution of signal that results from the need to include
heterogeneous populations and/or heterogeneous phenotypes.
For example, it is clear from studies on the hereditary forms of
breast cancer that mutations in the BRCA1 and BRCA2 genes are
often specific to individual populations [13]. If distinct sub-
phenotypes are due to different susceptibility genes, a study that
combines these heterogeneous phenotypes will yield diluted effects.
A smaller number of rare medium- to high-penetrant variants
are needed to account for the heritability. The current SNP array
platforms are not able to genotype very rare SNPs, but,
surprisingly, if denser arrays were available and the ORs were of
medium size (e.g, 1.28 to 2.01 in model D), we would only need
modestly large sample sizes to detect these rare variants. Such
sample sizes are comparable to many existing genome-wide
association studies, so they are well within reach. We might also
search for higher-penetrant variants in subsets of populations, for
example, by more strictly-defined phenotypes or by studying
familial cases.
One natural question about the rare-variant model with large
effect-sizes (e.g., model E) is whether existing data already rule it
out. Is it possible to miss such rare alleles using the existing tagging
SNPs? The case of the CHEK2 1100delC mutation is a relevant
example. It has an allele frequency of approximately 0.5% and an
OR of 2.7 for sporadic breast cancer and 4.8 for familial breast
cancer [14]. Yet the CHEK2 gene does not appear among the top
SNPs in the largest most recent breast cancer association study [3].
So rare-variant model with large effect-sizes is still a possibility.
Very rare variants (MAFsv0.01) will create methodological
problems. First of all, they are not represented in the current
highest-density genotyping arrays. Another problem is the
measurement accuracy: since genotype calling is based on
fluorescent intensity and clustering, it will be hard to distinguish
very rare variants from genotyping errors. Also, as they are likely
to occur after the out-of-Africa migration, rare variants are likely
to be population specific, which means that we cannot simply
combine different study cohorts. Some of these problems might be
solved by the complete sequencing method, but this technology is
still too expensive for large studies.
Age-related macular degeneration [15] and exfoliation glauco-
ma [16] are unusual among phenotypes studied through GWAS,
with large effects from common variants that have been identified
in limited samples. Nonetheless, they show that there are traits
with marked allelic homogeneity. Other very recent example is
transferrine concentration [17], where 40% of the variance is
explained by a single locus. However, it is impossible to judge
beforehand which complex traits will display such a genetic
architecture.
To appreciate the scope of our challenge in genetic dissection of
complex phenotypes, it is useful to consider the genetics of cystic
fibrosis (CF), a ‘simple’ Mendelian disease of the mucus glands of
the lungs, liver and pancreas. CF is a recessive disorder, caused by
mutations in CFTR, a 230,000-base long gene on chromosome
7q31.2. Deletion of codon 508 (phenylalanine), first identified in
1988 [18], is found in 66% of the cases. However, there are more
than 1000 other deleterious mutations, a great majority of which
are very rare variants. It is known that the clinical manifestations
of the disease, for example prognosis, vary substantially; while
these correlate with the type of mutations [19,20], the genotype
explains only a small portion of the clinical variability.
This highlights two salient points: (i) If a simple genetic disease
such as CF can have more than 1000 functional deleterious
variants, are there reasons to believe that the number and
spectrum of functional mutations (in terms of non-synonymous
substitutions, stop-mutations, deletions, splice mutations etc.,)
should be different for genes with more subtle effects on complex
diseases? (ii) Monogenic diseases such as CF also have phenotypic
diversity, and this diversity is still poorly explained by the
underlying genetics. If anything, the phenotypic diversity of within
each complex disease tends to be wider than that of simple
Mendelian diseases, so our challenge will be even greater.
Different disease subtypes are likely due to different (combinations
of) causal variants; however, due to sample-size problems, our
case-control samples are combined over these subtypes, so, the
effects of the functional variants will be diluted. In conclusion,
substantial challenges remain in finding genetic explanation of the
common diseases.
Materials and Methods
Heterogeneity in Susceptibility
In quantitative genetic analysis of a complex disease we usually
assume a latent susceptibility (or liability) that varies between
individuals [21]. The liability can be due to genetic and
environmental factors; heritability is the proportion of the variance
in liability due to genetic factors. Putting existing discoveries into
this framework helps answer our questions.
Starting with the estimated odds-ratio and allele frequency for
each SNP, assume that the SNPs act independently and
multiplicatively. Suppose we have K SNPs with MAF p1,...,pK.
Each SNP generates 3 genotypes (AA, AB or BB) with frequencies
p2
k, 2pk 1{pk ðÞ and 1{pk ðÞ
2. Assuming the K SNPs combine
Genetic Variants
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associated log OR and proportion given by:
logOR~
X
k
aklogORk ð1Þ
p~P
k
qk, ð2Þ
where the sum and the product is over different SNPs in the
configuration, ak is the number of risk alleles (0, 1 or 2) and qk is the
frequency of the k th genotype; qk[ p2
k,2pk 1{pk ðÞ ,1 {pk ðÞ
2
no
depending on the genotype.
The collection of log ORs with its proportions represents the
risk distribution implied by the collection of SNPs. For K~20, the
total number of combinations 3K is very large, so we need to group
the log ORs into intervals and combine the proportions
accordingly. Such grouping is also useful for plotting; see Figure 2.
From the risk distribution we can evaluate its variance. Since
each term in the summation (1) is a scaled-binomial variate with
parameters 2,pk ðÞ and log OR as the scale, the variance of the
distribution is given by
var~2
X
pk 1{pk ðÞ logORk ðÞ
2:
Here we see the relationship between the number of variants and
the variance of the risk distribution: if we add more variants into
the formula above we will increase the variance. For example, if
we double the number of variants with another set that has similar
MAFs and ORs, we will double the variance; i.e., the number of
variants varies linearly with the variance. Thus finding the number
of variants to achieve a certain variance is straightforward.
The number of variants is connected to heritability through the
variance. First note that the log OR in Figure 2 corresponds
directly to the latent susceptibility model well known in statistical
genetics:
logitp~b0zg, ð3Þ
with random genetic effect g distributed as N 0,var g ðÞ ðÞ (e.g.,
[22]). In this model, the constant term b0 is determined the overall
prevalence of the disease. The contribution of the genetic factors
to the liability of the disease is so-called heritability:
h2~
var g ðÞ
var g ðÞ zp2=3
, ð4Þ
where p2 
3 is the variance of the standard logistic distribution
[22].
Sample Size Computation
For each SNP, consider the observed log OR as the test statistic,
and let h be the true OR. In a case-control study of n cases and n
controls, the observed log OR is approximately N m,s2   
, with
m~logh ð5Þ
s2~
1
np 1{p ðÞ
, ð6Þ
where p is the MAF of the SNP. The parameter h is the OR per
allele, and we assume Hardy-Weinberg equilibrium so each
subject contributes two independent alleles for each SNP.
To use the method in [9], we first need Fz ðÞ , which is the
marginal distribution of the statistics from all SNPs. In general,
accounting the contribution from all the SNPs, Fz ðÞwill follow a
mixture distribution of the form:
Fz ðÞ ~
ð
m,s2
w z;m,s2   
dG m,s2   
, ð7Þ
where the w z;m,s2   
is the normal density with mean m and
variance s2, and G m,s2   
is the joint distribution of mean and
variance of the log ORs across the SNPs. From (5) and (6),
G m,s2   
is determined by the joint distribution of true OR and
MAF across the SNPs. Thus we can study the effect of various
distributions of MAFs and ORs on the sample size needed to
detect the non-null SNPs. From the mixture model we can also get
F0 z ðÞ , the marginal distribution of the null SNPs, those that are
not associated with the case-control status.
In practice the joint distribution of ORs and MAFs is
discretized, as given in the example in the Results section, so the
mixture (7) becomes
Fz ðÞ ~
X
k
pkw z;mk,s2
k
  
,
where the index k runs over all possible (OR, MAF)-combinations,
and pk, mk and s2
k are the corresponding proportion, mean and
variance associated with the k th (OR, MAF)-combination. For
the null SNPs we get
F0 z ðÞ ~
X
k
pkw z;0,s2
k
  
,
where now k runs over all the (OR, MAF)-combinations with true
OR hk~1. These distributions give the false discovery rate (FDR),
using
FDR z ðÞ ~
p0P0 Z jj wz ðÞ
PZ jj wz ðÞ
,
where p0 is the proportion of null SNPs, assumed very close to
one, and P0 and P are the probabilities computed under the
distributions F0 and F, respectively. Once we have the FDR, we
can use the method in [9] to evaluate the sample size required to
achieve a certain FDR level. Finally, given a certain FDR level, the
expected number of discoveries in a collection of N top SNPs is
N 1{FDR ðÞ .
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